Skip to main content
Premium Trial:

Request an Annual Quote

Aiming for CLIA Certification, DermTech Begins Validation of Melanoma Test

Premium

DermTech said this week that it has begun commercial validation testing of its proprietary pigmented lesion assay, a non-invasive qPCR-based test for melanoma.

The San Diego-based company recently completed the build-out of a commercial laboratory space in nearby La Jolla, Calif. The company needs to complete analytical and clinical validation studies of its assay in order to receive regulatory certification under CLIA requirements.

DermTech recently raised $5.6 million in a Series B financing led by Jacobs Investment Company, and will use a portion of these funds to complete the validation of its assays.

The company's assays analyze the expression level of multiple gene targets using Life Technologies' OpenArray quantitative real-time PCR system (PCR Insider 8/22/2013). DermTech's initial assay will identify expression consistent with melanoma. The test uses an adhesive-patch method to collect cells from pigmented lesions including melanomas, allowing for non-invasive sample collection.

DermTech is conducting the validation studies in collaboration with Northwestern University and the University of Pittsburgh Medical Center.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.